Prednisone Must Be Co-Administered with Abiraterone to Prevent Life-Threatening Mineralocorticoid Excess
Abiraterone must be given with concurrent corticosteroid—either oral prednisone 5 mg twice daily or oral methylprednisolone 4 mg twice daily—to prevent potentially dangerous mineralocorticoid excess that results from CYP17 inhibition. 1, 2
Primary Role: Prevention of Mineralocorticoid Toxicity
Abiraterone inhibits CYP17A1, which blocks androgen biosynthesis but simultaneously causes accumulation of mineralocorticoid precursors upstream of the enzymatic block. This leads to:
- Hypertension (22% incidence, 4% severe)
- Hypokalemia (17% incidence, 4% grade 3-4)
- Peripheral edema (28% incidence)
- Fluid retention (1% grade 3-4)
Without corticosteroid co-administration, these mineralocorticoid effects become clinically significant and potentially dangerous. In postmarketing surveillance, QT prolongation and Torsades de Pointes have been documented in patients who developed hypokalemia while on abiraterone 2. The prednisone acts as glucocorticoid replacement therapy, suppressing the compensatory ACTH rise that would otherwise drive excessive mineralocorticoid production 4.
Dosing Specifications
Standard regimen:
Alternative formulation:
- Fine-particle abiraterone 500 mg once daily + methylprednisolone 4 mg twice daily (FDA-approved bioequivalent alternative) 1
Cost-saving alternative:
- Abiraterone 250 mg once daily (with low-fat breakfast) + prednisone 5 mg twice daily—demonstrated non-inferiority in phase II trial 1
Required Monitoring Protocol
Because mineralocorticoid excess remains a risk even with corticosteroid co-administration, mandatory monthly monitoring includes:
- Liver function tests (ALT, AST, bilirubin)
- Serum potassium levels
- Serum phosphate levels
- Blood pressure measurements
Monitor every 2 weeks for the first 3 months, then monthly thereafter, as hepatotoxicity typically occurs within the first 3 months 2.
Critical Safety Considerations
Adrenal insufficiency risk: Patients are at risk for adrenocortical insufficiency if prednisone is interrupted, dose-reduced, or during periods of stress/infection. The mineralocorticoid excess symptoms can mask adrenal insufficiency signs 2. Increased corticosteroid doses may be needed during stressful situations.
Cardiovascular monitoring: Closely monitor patients with heart failure, recent MI, cardiovascular disease, or ventricular arrhythmia, as these conditions may be compromised by hypertension, hypokalemia, or fluid retention 2. Patients with LVEF <50% or NYHA Class III-IV heart failure were excluded from pivotal trials, so safety is not established in this population 2.
Some patients may avoid steroids: While guidelines note that some patients may be able to avoid steroids with careful monitoring, a mineralocorticoid receptor antagonist or steroid should be added immediately if side effects develop 3. This is not standard practice and requires intensive monitoring.
Alternative Steroid Strategy at Progression
For patients progressing on abiraterone plus prednisone, switching to dexamethasone 0.5-1 mg daily can extend benefit:
- 46.2% achieved ≥30% PSA decline at 6 weeks in the SWITCH study
- Median PFS of 10.35 months after the switch
- 56% experienced PSA stabilization or improvement
- Well-tolerated with no grade 3/4 toxicity
This represents a practical salvage strategy before moving to alternative systemic therapies.
Common Pitfall to Avoid
Never discontinue the corticosteroid while continuing abiraterone. The combination is FDA-approved specifically because the corticosteroid is essential for safety, not optional 2. Discontinuation risks severe mineralocorticoid excess, potentially leading to cardiac arrhythmias from hypokalemia 2.